MedTrace Logo

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

NCT06076772 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2023-10-11

No results posted yet for this study

Summary

Aim of the study to assess the neutropenia induced by Palbociclib in patient receiving Palbociclib in combination with hormonal treatment as first-line therapy in metastatic hormone receptor- positive HER2 negative breast cancer. To evaluate the risk factors for occurrence of neutropenia and treatment outcome as 2 years PFS and OS.

Conditions

Interventions

DRUG

Palbociclib

The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06076772 on ClinicalTrials.gov